Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease

V Dartois, T Dick - Nature Reviews Drug Discovery, 2024 - nature.com
Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection

PK Drain, KL Bajema, D Dowdy, K Dheda… - Clinical microbiology …, 2018 - journals.asm.org
Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a
limited understanding of its clinical pathogenic spectrum of infection and disease …

Antibiotics in the clinical pipeline in October 2019

MS Butler, DL Paterson - The Journal of antibiotics, 2020 - nature.com
The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR)
bacteria, especially Gram-negative (G− ve) pathogens, is acknowledged as one of the …

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

K Dheda, T Gumbo, G Maartens, KE Dooley… - The lancet Respiratory …, 2017 - thelancet.com
Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Tuberculous meningitis

RJ Wilkinson, U Rohlwink, UK Misra… - Nature reviews …, 2017 - nature.com
Tuberculosis remains a global health problem, with an estimated 10.4 million cases and 1.8
million deaths resulting from the disease in 2015. The most lethal and disabling form of …

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

S Tiberi, N Du Plessis, G Walzl, MJ Vjecha… - The Lancet Infectious …, 2018 - thelancet.com
Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …

Mycobacterium smegmatis: the vanguard of mycobacterial research

IL Sparks, KM Derbyshire, WR Jacobs Jr… - Journal of …, 2023 - journals.asm.org
The genus Mycobacterium contains several slow-growing human pathogens, including
Mycobacterium tuberculosis, Mycobacterium leprae, and Mycobacterium avium …

The treatment of tuberculosis

CA Peloquin, GR Davies - Clinical Pharmacology & …, 2021 - Wiley Online Library
Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a
major driver. Clinically, TB presents as “latent” TB and active TB disease, and the treatment …

Mechanisms of drug-induced tolerance in Mycobacterium tuberculosis

SN Goossens, SL Sampson… - Clinical microbiology …, 2020 - journals.asm.org
Successful treatment of tuberculosis (TB) can be hampered by Mycobacterium tuberculosis
populations that are temporarily able to survive antibiotic pressure in the absence of drug …

The pathogenesis of tuberculous meningitis

AG Davis, UK Rohlwink, A Proust… - Journal of leukocyte …, 2019 - academic.oup.com
Tuberculosis (TB) remains a leading cause of death globally. Dissemination of TB to the
brain results in the most severe form of extrapulmonary TB, tuberculous meningitis (TBM) …